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INTRODUCTION 
Schizophrenia is a devastating emotional, physical and
mental disorder. One percent of the US population is afflict-
ed with schizophrenia, and antipsychotics have become the
first-line treatment for schizophrenia as well as for other psy-
chotic disorders (1). Recently developed antipsychotics gen-
erally possess a similar efficacy compared to older antipsy-
chotics, but they have a better side-effect profile, especially
with regard to extrapyramidal symptoms and tardive dyski-
nesia (2). The increased use of second-generation antipsy-
chotics over the last decade has raised concerns about their
metabolic side effects, such as weight gain, diabetes and dys-
lipidemia (3, 4). 
Obesity, dyslipidemia and diabetes have serious implica-
tions for overall health and survival because they are associ-
ated with an increased risk for cardiovascular and malignant
disorders (5). In addition, medication-induced weight gain
has been associated with a lower quality of life (6) and non-
compliance (7), which increases the risk for relapse (8). Among
the atypical antipsychotics, significantly more weight gain
occurred during treatment with olanzapine than with other
antipsychotics (9). However, the mechanisms of weight gain
and dyslipidemia are poorly understood, and various parts
of the endocrine system are presumably involved in these
side effects.
The hypothalamus has been recognized as a major site of
energy homeostasis in the central nervous system (10). Recent
studies have shown that the hormones leptin and ghrelin are
crucial elements of the hypothalamic neurocircuitry. Leptin
is one of a number of cytokine-like molecules synthesized in
adipose tissue. It is actively transported into the hypothala-
mus, where it acts to limit food intake (11). It also directly
influences insulin secretion (12). Thus, leptin has been inten-
sively investigated with respect to its association with changes
in weight and glucose metabolism during treatment with
various antipsychotics (13). Ghrelin is a recently discovered
orexigenic hormone that is primarily secreted by the stom-
ach and duodenum, and it has been implicated in both meal-
time hunger and the long-term regulation of body weight
(14). Ghrelin is currently recognized as the main endoge-
nous ligand for growth hormone secretagogue receptors, as
well as other regulatory factors in growth hormone (GH)
secretion and energy balance (15). The levels of circulating
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Body Weight and Plasma Levels of Ghrelin and Leptin during 
Treatment with Olanzapine
Although enhanced appetite and weight gain are potential side effects of treatment
with antipsychotic agents, particularly olanzapine and clozapine, the mechanisms
underlying these side effects are poorly understood. Leptin and ghrelin were recently
identified as hormones that play crucial roles in the regulation of energy balance
and glucose metabolism. To elucidate relationships between weight change and
plasma levels of ghrelin and leptin, we investigated the circulating ghrelin and lep-
tin levels and body weight during olanzapine treatment. Twenty-four patients with
schizophrenia were examined during 6-month administration of olanzapine. Ghre-
lin, leptin, weight and body mass index (BMI) were measured before and after 2, 4,
8, 12, 16, and 24 weeks of olanzapine treatment. The concentration of glucose and
various lipid metabolic parameters were measured at baseline and at 24 weeks.
Significant increases in weight, BMI and leptin were observed at week 24. On the
other hand, the serum levels of ghrelin decreased significantly after olanzapine
treatment. In addition, the level of ghrelin was negatively correlated with the leptin
level, BMI and weight. The leptin level was positively correlated with both BMI and
weight. Ghrelin is associated with metabolic changes, in combination with leptin,
during olanzapine treatment. However, further large-scale and longitudinal studies
are warranted to elucidate the metabolic changes involving ghrelin, leptin and insulin
during treatment with antipsychotics.
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ghrelin are increased under conditions of starvation and in
anorexia nervosa, but decreased under conditions of feeding
and in obesity (16, 17). Ghrelin has been shown to play cru-
cial roles in the regulation of energy balance and glucose
metabolism in combination with leptin. Ghrelin and leptin
may have opposite actions in the regulation of body weight
(18).
This study was designed to investigate the relationships
between weight gain and plasma levels of ghrelin and leptin
because the correlation between olanzapine-induced weight
gain and changes in plasma levels of ghrelin and leptin was
not fully described in previous studies. 
MATERIALS AND METHODS
Subjects
The subjects of this study were 24 male in-patients in the
Department of Psychiatry at Hadong Wooridle Hospital in
Korea who fulfilled the DSM-IV diagnostic criteria for schi-
zophrenia. We chose to study only males because gender dif-
ferences in the effects of antipsychotic drugs on weight have
not been fully investigated. The exclusion criteria were: 1)
patients who had a substance-related disorder or other phys-
ical illness, including hypertension or hyperlipidemia, that
might affect their appetite or glucose metabolism; 2) signif-
icant weight loss/gain ±1 kg in the past 8 weeks. The pati-
ents underwent a screening evaluation followed by a washout
period of up to 2 weeks if they had received any antipsy-
chotic medication. Each subject was informed of the pur-
pose, procedures, and potential risks of participation in the
study before signing an informed consent form.
Procedure 
Olanzapine was initially administered at a dose of 5-20
mg once daily. The dose was increased at weekly intervals
based on clinical improvement. Benzodiazepines were per-
mitted to control nonpsychotic symptoms like anxiety. Body
weight, body mass index (BMI) and plasma levels of ghrelin
and leptin were assessed at baseline and after 2, 4, 8, 12, 16,
and 24 weeks. Glucose, total cholesterol, high density lipopro-
tein (HDL)-cholesterol, low density lipoprotein (LDL)-choles-
terol and triglyceride levels were assessed at baseline and at
24 weeks. All meals were prepared and provided by the kitchen
staff at Wooridle Hospital. 
Blood samples
The author collected 10-12 mL venous blood samples
between 7:00 am and 8:00 am after overnight fasting. The
samples were immediately analyzed for glucose, total choles-
terol, HDL-cholesterol, LDL-cholesterol, and triglycerides.
The samples to be analyzed for ghrelin and leptin were imme-
diately centrifuged and stored at -80℃ until thawing for
analysis. Plasma concentrations of ghrelin and leptin were
determined using a commercially available radioimmunoas-
say system at Gyeongsang National University (ghrelin:
LINCO Research Inc., Mo, U.S.A.; Leptin: LINCO Research,
Mo, U.S.A.).
Statistics
Analysis of variance (ANOVA) with repeated measure was
used to evaluate ghrelin, leptin, weight and BMI at the med-
ication-free stage and after treatment in those subjects who
had data for all of the time points. Differences in glucose, total
cholesterol, HDL-cholesterol, LDL-cholesterol and triglyc-
eride levels before and after olanzapine treatment were com-
pared using the paired t-test. Pearson correlation coefficient
analyses were used to examine the correlation between changes
in weight, BMI, ghrelin and leptin levels following treat-
ment with olanzapine. p<0.05 was considered statistically
significant in all analyses. All statistical analyses were per-
formed using SPSS software (version 11.0).
RESULTS 
A total of 24 patients with schizophrenia met our inclu-
sion criteria. Most of the patients were diagnosed with para-
noid schizophrenia according to DSM-IV diagnostic criteria
for subtypes of schizophrenia. The only other subtype observ-
ed in our patients was undifferentiated schizophrenia. All
patients completed the full 24-week study. The mean age of
Measure
Mean (SD)
Baseline Week 2 Week 4 Week 8 Week 12 Week 24 F p Week 16
Statistics*
Weight (kg) 62.5 (7.8) 63.2 (8.1) 64.0 (7.9) 65.1 (7.9) 65.6 (8.4) 67.0 (8.9) 68.0 (10.1) 14.0 <0.01
BMI (kg/m
2) 21.3 (2.0) 21.6 (2.1) 21.8 (2.0) 22.2 (2.0) 22.4 (2.0) 22.8 (2.2) 23.2 (2.5) 16.5 <0.01
Leptin (ng/mL) 3.0 (1.3) 3.3 (1.5) 3.6 (1.5) 3.8 (1.6) 4.0 (1.7) 4.1 (1.7) 4.1 (1.8) 11.5 <0.01
Ghrelin (pg/mL) 45.3 (10.1) 40.9 (10.2) 41.4 (9.9) 38.2 (10.9) 37.1 (11.0) 34.8 (9.5) 32.7 (10.1) 17.8 <0.01
Table 1. Body weight, body mass index (BMI), plasma leptin levels and ghrelin levels in patients with schizophrenia during olanzap-
ine treatment
*, ANOVA with repeated measures. BMI, body mass index.Ghrelin, Leptin and Olanzapine Induce Weight Gain  687
the patients treated with olanzapine was 34.3±6.5 yr. The
mean daily dose used by the patients at week 24 was 11.7±
3.1 mg. 
The changes in ghrelin, leptin, weight and BMI are shown
in Table 1. The BMI (F=16.5, p<0.001) and weight (F=14.0,
p<0.001) of the patients increased significantly during the
period of treatment with olanzapine. The patients were an
average 5.5 kg heavier at week 24 than they were at baseline.
Plasma leptin levels also increased significantly during olan-
zapine treatment (F=11.5, p<0.001). However, plasma ghrelin
levels decreased significantly (F=17.8, p<0.001). 
The change in plasma ghrelin levels was significantly cor-
related with the changes in BMI (r=-0.481, p=0.017) and
weight (r=-0.411, p=0.046) (Fig. 1A), while the change in
plasma leptin levels was significantly correlated with the
changes in BMI (r=0.784, p<0.001) and weight (r=0.773,
p<0.001) (Fig. 1B). The level of ghrelin (r=-0.724, p<0.001)
correlated negatively with the level of leptin (Fig. 2). 
The level of glucose and lipid metabolic parameters in
patients with schizophrenia during olanzapine treatment are
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Fig. 1. Correlation between changes in the plasma levels of ghrelin (pg/mL) and leptin (ng/mL) and body weight (kg) in patients with schi-
zophrenia during 24 weeks of treatment with olanzapine. Ghrelin and body weight (A), leptin and body weight (B). The change in weight
was significantly correlated with the change in the plasma levels of ghrelin (r=-0.411, p=0.046) and the plasma levels of leptin (r=0.773,
p<0.001).
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Parameter 
Time
Baseline, mean (SD) Week 24, mean (SD) df p t
Statistics*
Fasting glucose (mg/dL) 89.2 (7.8) 91.1 (9.0) -0.91 23 0.373
Total cholesterol (mg/dL) 172.2 (10.8) 192.3 (19.9) -4.29 23 <0.001
Triglyceride (mg/dL) 116.8 (10.4) 123.8 (7.7) -2.42 23 0.024
LDL-cholesterol (mg/dL) 112.1 (14.0) 119.0 (12.9) -1.67 23 0.109
HDL-cholesterol (mg/dL) 50.4 (8.7) 47.7 (9.5) 2.28 23 0.033
Table 2. The levels of glucose and lipid metabolic parameters in patients with schizophrenia during olanzapine treatment
*, paired t-test.
LDL, low density lipoprotein; HDL, high density lipoprotein; SD, standard deviation.
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Fig. 2. Correlation between the changes in the circulating plasma
levels of ghrelin (pg/mL) and leptin levels (ng/mL) in patients with
schizophrenia during 24 weeks of treatment with olanzapine. The
change in plasma levels of leptin was significantly correlated with
the change in plasma levels of ghrelin (r=-0.724, p<0.001).688 B.-J. Kim, J.-W. Sohn, C.-S. Park, et al.
shown in Table 2. The concentrations of glucose (t=-0.91,
df=23, p=0.373) and LDL-cholesterol (t=-1.67, df=23, p=
0.109) did not change significantly from the baseline values
after 24 weeks. However, the concentrations of total choles-
terol (t=-4.293, df=23, p<0.001), HDL-cholesterol (t=2.28,
df=23, p=0.033) and triglycerides (t=-2.42, df=23, p=0.024)
changed significantly.
DISCUSSION 
Many reports have suggested that olanzapine induces weight
gain (19). However, the mechanism behind this weight gain
remains unclear. It was recently found that appetite and body
weight are controlled by complex hypothalamic neurocir-
cuitry, and that the hormones leptin and ghrelin are crucial
elements of this control system. The circulating concentra-
tion of leptin is directly proportional to adiposity and func-
tions within the hypothalamus to limit food intake, while
ghrelin is synthesized in the stomach and functions within
the hypothalamus to stimulate food intake (20-22). A few
studies investigated the association of leptin and ghrelin with
weight changes and glucose metabolism during treatment
with antipsychotics. Previous studies have reported an increase
in circulating leptin in patients treated with olanzapine (23,
24). However, Hosojima et al. reported that ghrelin levels
decreased after the initiation of olanzapine therapy and sug-
gested that ghrelin is associated with metabolic changes in
combination with leptin, during treatment with olanzapine
(25). Potential limitations of previous studies include the
relatively short duration of exposure and the evaluation of a
relatively small number of subjects. Thus, we conducted a
prospective study using the changes in plasma levels of ghre-
lin, leptin and body weight to elucidate the relations with
each other behind the weight gain observed in 24 patients
with schizophrenia after 24 weeks of treatment with thera-
peutic doses of olanzapine.
In the present study, we demonstrated that plasma ghre-
lin levels decreased significantly during olanzapine treat-
ment, while plasma leptin levels and BMI increased signifi-
cantly during treatment with olanzapine. Leptin has been
intensively investigated with respect to association with obe-
sity induced antipsychotics. Previous studies have reported
an increase in leptin in subjects treated with olanzapine (23).
And this was corroborated by our results. Results of the pre-
sent study correspond with the results of earlier studies which
reported that ghrelin was reduced in obesity and weight gain.
Tschop et al. reported that, in humans, fasting plasma ghre-
lin was reduced in obese subjects in comparison to lean sub-
jects (26). In rodents, subcutaneous, intracerebroventricular
and intraperitoneal administration of ghrelin stimulates feed-
ing, reduces fat utilization and increases body weight (27,
28). Furthermore, Hansen et al. reported that ghrelin is sup-
pressed in most cases of obesity and is not a causal factor in
the pathogenesis of obesity (29). These data seem to indicate
that ghrelin is downregulated as a consequence of excess ener-
gy in obese subjects. Therefore, we suggest that ghrelin may
be downregulated as a consequence of obesity induced by olan-
zapine, showing a normalizing effect on energy homeostasis
and metabolic change induced by olanzapine.
Another finding is that the level of ghrelin is negatively
correlated with the level of leptin, BMI, and weight. Ghre-
lin and leptin secretions are apparently regulated by disparate
mechanisms because no temporal synchrony was observed
in the episodic discharge of these hormones in sated rats (30).
However, Kalra et al. reported that fasting increased ghrelin
secretion by triggering high-amplitude pulses at a greater
frequency in synchrony with leptin pulses of markedly reduced
amplitude (31). In addition, Ueno et al. found that the increas-
ed ghrelin expression in ob/ob mice was downregulated by
leptin administration and suggested that leptin is an upstream
regulator of gastric ghrelin (32). These studies support our
result that ghrelin levels are negatively correlated with the
leptin levels. Our results are consistent with previous stud-
ies, suggesting that ghrelin is downregulated by increased
leptin following weight gain induced by olanzapine. 
In this study, no significant changes in the levels of glu-
cose and LDL-cholesterol were observed. However, serum
levels of HDL-cholesterol, total cholesterol and triglycerides
changed significantly. In a previous study, Huang et al. report-
ed that triglyceride levels increased significantly 3 weeks
after treatment with olanzapine (33). Furthermore, Brown
and Estoup reported that olanzapine-treated patients showed
adverse changes in all measured metabolic parameters, with
increases in total cholesterol and triglycerides reaching a sta-
tistical significance (34). In addition, several previous stud-
ies have emphasized that individuals most at risk for the devel-
opment of coronary heart disease are those with combined
dyslipidemia (35). The results of our study and previous stud-
ies indicate that regular health screenings are needed in pati-
ents with schizophrenia. These findings also suggest that
psychiatrists should discuss the potentially serious side effects
of olanzapine with patients prior to initiating treatment and
provide psychoeducation concerning the management of the
metabolic side effects of olanzapine.
A possible first limitation of this study is that only male
patients were included. Second limitation of this study is
that all of the subjects in this study were within the normal
weight range, although the patients with schizophrenia pati-
ents tended to have higher body weights than the healthy
individuals. Therefore, the generalization of these results to
all schizophrenia is limited. Third limitation is that Benzo-
diazepines were permitted to control the nonpsychotic symp-
toms. Even though these are not known to affect appetite
and glucose metabolism definitely, There are some possibil-
ity of risk to increase appetite (36) and might affect the result
of this study. Additionally, feeding behavior is extremely
complicated because it involves many factors, including emo-Ghrelin, Leptin and Olanzapine Induce Weight Gain  689
tion, memory, learning, and various cognitive factors. How-
ever, in this study, the possible existence of many physiolog-
ical and behavioral factors that modulate weight gain was
not considered. Therefore, further long-term studies must
be conducted taking these factors into consideration.
In summary, treatment with olanzapine is associated with
weight gain and increases in BMI. Ghrelin correlates nega-
tively with weight gain and BMI during olanzapine treat-
ment. Leptin, on the other hand, shows a positive correla-
tion with weight gain and BMI during olanzapine treatment.
However, the generalization of the study results to all patients
with schizophrenia is limited because various parts of the
endocrine system and genetic factors are presumably involv-
ed in the effect of antipsychotics on weight gain. Therefore,
further large-scale and longitudinal studies are warranted to
evaluate the many processes involving ghrelin and leptin
during treatment with olanzapine and other antipsychotics.
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